natgillin/translations-raw huggingface dataset:
Patients must not receive growth factor treatment such as G-CSF for 3 weeks prior to Zevalin administration as well as for 2 weeks following completion of the treatment in order to assess the adequate bone marrow reserve correctly and because of the potential sensitivity of rapidly dividing myeloid cells to radiation (see also section 4.5). 
Zaradi pravilne ocene rezerve kostnega mozga in možne občutljivosti hitro delečih se mieloičnih celic na sevanje, bolniki ne smejo biti zdravljeni z rastnim faktorjem (npr. G-CSF) 3 tedne pred zdravljenjem z zdravilom Zevalin in še 2 tedna po končanem zdravljenju (glejte tudi poglavje 4.5).
A total of 73 patients received the Zevalin therapeutic regimen, and 70 patients received rituximab given as an intravenous infusion at 375 mg/m weekly times 4 doses. 
V študijo je bilo vključenih 143 bolnikov, ki pred tem niso prejemali rituksimaba, z recidivnim ali neodzivnim nizkostopenjskim ali folikularnim ne-Hodgkinovim limfomom (NHL) ali z NHL s transformacijo celic B. Skupno 73 bolnikov je dobivalo terapevtsko shemo z zdravilom Zevalin, 70 bolnikov pa je dobilo rituksimab v obliki intravenske infuzije 4 odmerkov po 375 mg/m na teden.
Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. 
Konsolidacijska terapija po nastopu remisije pri predhodno nezdravljenih bolnikih s folikularnim limfomom
Before administration to the patient, the percent radioincorporation of the prepared Y]-radiolabelled Zevalin must be checked according to the procedure outlined in section 12. 
Pred dajanjem zdravila bolniku je treba preveriti odstotek radiooznačenosti pripravljenega z [
Respiratory, thoracic, and mediastinal disorders 
Bolezni dihal, prsnega koša in mediastinalnega prostora kašelj, rinitis
Y]-radiolabelled Zevalin solution. 
Y] označenega zdravila Zevalin.
After you are given Zevalin 
Po prejemu zdravila Zevalin
Severe mucocutaneous reactions, including Stevens-Johnson Syndrome, some with fatal outcome, have been reported in association with Zevalin after pretreatment with rituximab. 
Redko so poročali, da je bilo zdravljenje z zdravilom Zevalin po predhodnem zdravljenju z rituksimabom povezano s pojavom hudih reakcij kože in sluznic, vključno s Stevens-Johnsonovim sindromom, ki je bil v nekaterih primerih smrten.
• NHL with CNS involvement 
• NHL s prizadetostjo osrednjega živčevja
Animal reproduction studies were not conducted with ibritumomab tiuxetan. 
Vpliva ibritumomab tiuksetana na sposobnost razmnoževanja pri živalih niso raziskovali.
Extravasation with subsequent infusion site reactions, Damage to lymphomasurrounding tissue and complications due to lymphoma swelling 
bolečina, simptomi, podobni gripi, slabotnost, periferni edem, povečano potenje ekstravazacija z naknadno reakcijo na mestu infundiranja, poškodovanje tkiva okoli limfoma in zapleti zaradi oteklega limfoma
Y]- or 
Y] ali [
Zevalin 1.6 mg/ml kit for radiopharmaceutical preparations for infusion 
Zevalin 1,6 mg/ml komplet za pripravo radiofarmakov za infundiranje
Of these, grade 3 was common, grade 4 uncommon. 
Med spremljanjem so se okužbe pojavile pogosto, pri čemer je bila okužba 3. stopnje pogosta in 4. stopnje občasna.
- pain; flu-like symptoms; generally feeling unwell (malaise), swelling caused by build-up of fluid in the arms and legs and other tissues (peripheral oedema); increased sweating - high blood pressure (hypertension)** - low blood pressure (hypotension)** - absence of menstruation (amenorrhea)** 
- visok krvni pritisk (hipertenzija)** - nizek krvni pritisk (hipotenzija)** - izostanek menstruacije (amenoreja)**
Dizziness, Headache 
Bolezni živčevja vrtoglavica, glavobol
Pack size of 1 kit. 
Ovoj vsebuje 1 komplet.
• The active substance is ibritumomab tiuxetan. 
- Zdravilna učinkovina je ibritumomab tiuksetan.
- Pregnancy and lactation (see section 4.6). 
- preobčutljivost za rituksimab ali druge iz glodavcev pridobljene beljakovine; - nosečnost in dojenje (glejte poglavje 4.6).
Yttrium identification 
Identifikacija itrija
Y) radiolabelled ibritumomab tiuxetan. 
Y) označenega ibritumomab tiuksetana.
Estimated Radiation Absorbed Doses From [ 
Ocenjene absorbirane doze sevanja po aplikaciji z [
IBRITUMOMAB TIUXETAN SOLUTION VIAL 
VIALA Z RAZTOPINO IBRITUMOMAB TIUKSETANA
Organ region of interest Sacrum region of interest Whole body region of interest 
timus ščitnica ledvice celo telo
Amenorrhea** 
Motnje reprodukcije in dojk amenoreja**
Asthenia, Pyrexia, Rigors Fatigue** 
Splošne težave in spremembe na mestu aplikacije astenija, pireksija, okorelost, utrujenost**
Total Alpha impurities 
Skupne nečistote alfa pod mejo kvantifikacije*
Step 2: Clean your hands 
Korak 2: Očistite svoje roke
All three injection sites are equally suitable. 
Vsa tri mesta vnosa so enako primerna.
However, it can be interrupted at any time, if necessary. 
Vendar ga lahko prekinemo kadarkoli, če je potrebno.
Risk Management plan (RMP) 
· Načrt za obvladovanje tveganja (RMP)
Therefore, caution should be used in these patients. 
Pri teh bolnikih je zato potrebna previdnost.
(a) Summary of the safety profile 
(a) Povzetek varnostnega profila
Your doctor will decide which is best for you. 
Vaš zdravnik bo odločil o tem, kaj je najprimernejše za vas.
Choose one of the recommended injection sites as shown. 
Izberite eno od priporočenih mest injiciranja, kot je prikazano.
The frequency of possible side effects listed below: 
Pogostnost možnih neželenih učinkov je navedena spodaj:
Its use is limited to adult patients (aged 18 years or older). 
Uporaba tega zdravila je omejena le na odrasle bolnike (stare 18 let ali več).
Not included in the pack: 
V pakiranju ni vključeno:
· Let the skin dry for approximately 10 seconds. 
· Počakajte približno 10 sekund, da se koža posuši.
It is important to read and follow these instructions carefully so that you are able to use the pre-filled syringe correctly and safely. 
Pomembno je, da pazljivo preberete in sledite tem navodilom, da boste lahko napolnjeno injekcijsko brizgo uporabili pravilno in varno.
After preparation of the syringe as described in steps 1 to 5: 
Po pripravi injekcijske brizge, kot je opisano v korakih 1 do 5, sledi:
· You may see a drop of liquid at the end of the needle. 
· Na koncu igle lahko vidite kapljico tekočine.
• if you have high blood pressure that cannot be controlled 
· če imate visok krvni tlak, ki ni obvladljiv.
· The expiration date has passed. 
· če je rok uporabe že pretekel.
· Any part of the syringe appears to be damaged. 
· kateri koli del injekcijske brizge izgleda poškodovan.
Your doctor will consider what is the best treatment for you during pregnancy. 
Vaš zdravnik bo ocenil, katero zdravljenje je med nosečnostjo za vas najboljše.
Adverse reactions observed only during post-marketing are marked (*). 
Neželeni učinki, ki so jih opazili le po prihodu zdravila na trg, so označeni (*).
This means that you have too few red blood cells and your haemoglobin level is too low (your body's tissues might not receive enough oxygen). 
To pomeni, da imate premajhno število rdečih krvnih celic ter premajhno koncentracijo hemoglobina (vaša telesna tkiva lahko zato dobijo premalo kisika).
Pinching the skin is important to ensure that you inject under the skin (into fatty tissue) but not any deeper (into muscle). 
Kožna guba je pomembna, da zagotovite, da injicirate pod kožo (v maščobno tkivo) in ne globlje (v mišico).
This is important to ensure that the syringe and medicine are safe to use. 
To je pomembno, da zagotovite, da sta injekcijska brizga in zdravilo varna za uporabo.
Date of latest renewal: 15 May 2012 
Datum prve odobritve: 20. julij 2007 Datum zadnjega podaljšanja: 15. maj 2012
Injection into muscle could result in an uncomfortable injection. 
Injekcija v mišico bi lahko povzročila neprijeten občutek.
Tell your doctor if you are pregnant, think you are pregnant or intend to become pregnant. 
Obvestite zdravnika, če ste noseči, če mislite, da ste noseči ali nameravate zanositi.
For instructions on the administration of the medicinal product, see section 6.6. 
Za navodila glede uporabe zdravila glejte poglavje 6.6.
If clinically indicated, phlebotomy may be performed. 
Če je klinično indicirano, lahko opravimo flebotomijo.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you. 
Pred uporabo zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
It is recommended that haemoglobin is monitored every two weeks until stabilized and periodically thereafter. 
Priporočljivo je kontrolirati koncentracijo hemoglobina vsak drugi teden, dokler ni dosežena koncentracija stabilna, nato pa periodično.
· If needed, you may cover the injection site with a small bandage. 
· Če je treba, lahko mesto injiciranja pokrijete z majhnim povojem.
· Do not inject through clothing. 
· Ne injicirajte skozi obleko.
The rashes may progress to widespread peeling of the skin and life-threatening complications. 
Izpuščaji lahko napredujejo do razširjenega lupljenja kože in življenjsko ogrožajočih zapletov.
If you have any of these conditions, your doctor will discuss it with you and must treat you with caution. 
Če imate katero koli od navedenih stanj, se bo vaš zdravnik o tem pogovoril z vami in vas skrbno zdravil.
Treatment interruption 
Prekinitev zdravljenja
Your healthcare professional will always record the exact product you are using. 
Vaš zdravnik bo vedno zabeležil, točno katero zdravilo uporabljate.
Assemble all of the supplies you will need for an injection on a clean, well-lit flat surface such as a table. 
Zberite vse potrebno, kar potrebujete za injiciranje, na čisti ravni površini, kot je miza.
Push the plunger up slowly to the remove all air,, as shown to you by a healthcare professional. 
Bat počasi potisnite navzgor, da odstranite ves zrak, kot vam je pokazal zdravstveni delavec.
Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. 
Lahko se pojavijo tudi razjede v ustih, grlu, nosu, genitalijah in očeh (rdeče in otekle oči).
In clinical studies 24% of patients treated with MIRCERA were aged 65 to 74 years, while 20% were aged 75 years and over. 
V kliničnih preskušanjih je bilo 24 % bolnikov, zdravljenih z zdravilom MIRCERA, starih od 65 do 74 let, 20 % pa 75 let in več.
The average molecular mass is approximately 60 kDa of which the protein moiety plus the carbohydrate part constitutes approximately 30 kDa. 
Povprečna molekulska masa je 60 kDa, od tega prispevata proteinski in karbohidratni del približno 30 kDa.
· Read the packaging and ensure you have the dose prescribed by your healthcare professional. 
· Preberite navodila in se prepričajte, da imate odmerek, ki vam ga je predpisal zdravstveni delavec.
Do not attempt to administer an injection until you are sure that you understand how to use the pre-filled syringe. 
Ne poskušajte si dati injekcije, dokler niste popolnoma prepričani, da razumete, kako uporabljati napolnjeno injekcijsko brizgo.
Stevens-Johnson syndrome / toxic epidermal necrolysis* 
Stevens-Johnsonov sindrom / toksična epidermalna nekroliza*
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. 
Zaradi pomanjkanja študij o kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili.
The target haemoglobin concentration in two studies was >13 g/dl; in the remaining three studies it was 1214 g/dl. 
Ciljne koncentracije hemoglobina so bile v dveh študijah > 13 g/dl, v preostalih treh pa 12-14 g/dl.
Two controlled clinical studies in which epoetins were administered to patients with various cancers including head and neck cancers, and breast cancer, have shown an unexplained excess mortality. 
Dve kontrolirani klinični študiji, v katerih so epoetine dajali bolnikom z različnimi vrstami raka, vključno z rakom glave in vratu ter rakom dojk, sta pokazali nerazložljivo povečanje smrtnosti.
Keep the syringe dry. 
Injekcijska brizga mora ostati suha.
These serious skin rashes are often preceded by fever and/or flu-like symptoms. 
Pred temi hudimi kožnimi izpuščaji se pogosto pojavijo zvišana telesna temperatura in/ali gripi podobni simptomi.
· Do not warm up the syringe in any other way. 
· Injekcijske brizge ne segrevajte na kakršen koli drug način.
If you have these symptoms please contact your doctor immediately to receive treatment. 
Če imate te simptome, prosimo nemudoma obiščite zdravnika, da boste prejeli ustrezno zdravljenje.
Controlled clinical trials have not shown significant benefits attributable to the administration of epoetins when haemoglobin concentration is increased beyond the level necessary to control symptoms of anaemia and to avoid blood transfusion. 
Kontrolirana klinična preskušanja niso pokazala pomembnih koristi, ki bi jih pripisali dajanju epoetinov, če so koncentracije hemoglobina povečane nad raven, ki je potrebna za kontrolo simptomov anemije in izognitev transfuzijam krvi.
Deficiencies of iron, folic acid or vitamin B12 reduce the effectiveness of ESAs and should therefore be corrected. 
Pomanjkanje železa, folne kisline ali vitamina B12 zmanjša učinkovitost zdravil za stimulacijo eritropoeze, zato je treba ta stanja popraviti.
• If your doctor suspects or confirms that you have these antibodies in your blood, you must not be treated with MIRCERA. 
· Če vaš zdravnik sumi ali potrdi, da imate ta protitelesa v krvi, se ne smete zdraviti z zdravilom
MIRCERA has no or negligible influence on the ability to drive and use machines. 
Zdravilo MIRCERA nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Dose adjustments should not be made more frequently than once a month. 
Odmerka naj ne bi prilagajali pogosteje kot enkrat na mesec.
You should discuss options for anemia treatment with your doctor. 
O možnostih zdravljenja anemije se posvetujte z zdravnikom.
The sterile pre-filled syringe does not contain any preservative and is to be used for a single injection only. 
Sterilna napolnjena injekcijska brizga ne vsebuje konzervansov in je namenjena le za enkratno injiciranje.
Pure red cell aplasia* 
neznana čista aplazija rdečih krvnih celic*
Studies in animals have shown no evidence of impaired fertility (see section 5.3). 
Študije na živalih niso pokazale škodljivih vplivov na plodnost (glejte poglavje 5.3).
Frequency categories are defined using the following convention: very common (³1/10); common (³1/100 to <1/10); uncommon (³1/1,000 to <1/100); rare (³1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). 
Za razvrstitev pogostnosti je uporabljen naslednji dogovor: zelo pogosti (³ 1/10), pogosti (³ 1/100 do < 1/10), občasni (³ 1/1.000 do < 1/100), redki (³ 1/10.000
Individual responsiveness must be considered when treatment is initiated. 
Pri uvajanju zdravljenja je treba upoštevati individualni odziv.
As with all growth factors, there is a concern that ESAs could stimulate the growth of any type of malignancy. 
Kot pri vseh rastnih dejavnikih obstaja bojazen, da zdravila, ki spodbujajo eritropoezo, lahko spodbujajo tudi rast katerekoli malignosti.
Treatment with MIRCERA is normally long-term. 
Zdravljenje z zdravilom MIRCERA je običajno dolgotrajno.
Follow the recommendations of your healthcare professional about how you should inject MIRCERA. 
Sledite navodilom vašega zdravstvenega delavca, kako si naj bi injicirali zdravilo MIRCERA.
· Do not touch the needle or let it touch any surface, as the needle may become contaminated and may cause injury and pain if touched. 
· Igle se ne dotikajte in ne pustite, da se dotakne katere koli površine, ker se lahko okuži in lahko povzroči poškodbo in bolečino, če se jo dotaknemo.
What MIRCERA is and what it is used for What you need to know before you use MIRCERA How to use MIRCERA 
Kaj je zdravilo MIRCERA in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo MIRCERA Kako uporabljati zdravilo MIRCERA
Now, the tear-off label can be removed, if necessary. 
Če je potrebno, lahko sedaj odstranite nalepko.
Treatment with MIRCERA must be started under the supervision of a healthcare professional. 
Zdravljenje z zdravilom MIRCERA je treba začeti pod nadzorom zdravstvenega delavca.
Examine the syringe and check the expiration date on the syringe and box. 
Preglejte injekcijsko brizgo in preverite rok uporabnosti na injekcijski brizgi in škatli.
Further injections can be given by a healthcare professional or, after you have been trained, you can inject MIRCERA yourself (see instructions at the end of this leaflet.) 
Naslednje injekcije vam lahko daje zdravstveni delavec ali pa si zdravilo MIRCERA injicirate sami potem, ko so vas o tem ustrezno poučili (glejte napotke na koncu tega navodila za uporabo).
There are no data from the use of MIRCERA in pregnant women. 
Ni podatkov o uporabi zdravila MIRCERA pri nosečnicah.
· Do not touch the release clips (see diagram below) as this may damage the syringe and make it unusable. 
· Ne dotikajte se sprostitvene sponke (glejte sliko spodaj), ker to lahko poškoduje injekcijsko brizgo in jo naredi neuporabno.
What MIRCERA is and what it is used for 
Kaj je zdravilo MIRCERA in za kaj ga uporabljamo
It can, however, be stopped on the advice of your doctor at any time. 
Po nasvetu zdravnika ga lahko kadar koli prekinete.
Supplementary iron therapy is recommended for all patients with serum ferritin values below 100 microgram/l or with transferrin saturation below 20%. 
Jemanje železovih pripravkov je priporočljivo za vse bolnike, ki imajo serumsko koncentracijo feritina pod 100 mikrogramov/l ali nasičenost transferina pod 20 %.
Haemoglobin concentration: In patients with chronic kidney disease, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration recommended in section 4.2. 
Koncentracija hemoglobina: Pri bolnikih s kronično ledvično odpovedjo vzdrževana koncentracija hemoglobina ne sme preseči zgornje meje ciljne koncentracije hemoglobina, priporočene v poglavju 4.2.
Since the treatment experience is limited in patients on peritoneal dialysis, regular haemoglobin monitoring and strict adherence to dose adjustment guidance are recommended in these patients. 
Ker so izkušnje z zdravljenjem pri bolnikih na peritonealni dializi omejene, je pri teh bolnikih priporočljivo redno spremljanje koncentracij hemoglobina in dosledno upoštevanje navodil za prilagajanje odmerkov.
MIRCERA pre-filled syringe Instructions For Use 
MIRCERA napolnjena injekcijska brizga Navodila za uporabo
This medicine is prescribed to you because you have anaemia caused by your chronic kidney disease and associated whith typical symptoms, such as tiredness, weakness and shortness of breath. 
Zdravilo so vam predpisali, ker imate anemijo, ki jo je povzročila kronična bolezen ledvic in je povezana s tipičnimi simptomi, kot so utrujenost, oslabelost in pojemanje sape.
To ensure effective erythropoiesis, iron status has to be evaluated for all patients prior to and during treatment. 
Za zagotovitev učinkovite eritropoeze je treba vsem bolnikom pred začetkom zdravljenja in med samim zdravljenjem kontrolirati status železa.
In a six-month rat toxicity study no tumorigenic or unexpected mitogenic responses were observed in non-haematological tissues. 
V šestmesečni študiji toksičnosti pri podganah v nehematoloških tkivih niso opazili tumorogenega ali nepričakovanega mitogenega odziva.
During clinical studies patients had a slight decrease in their platelet blood counts. 
Med kliničnimi študijami so bolniki imeli malenkostno znižano število trombocitov v krvi.
A common side effect (may affect up to 1 in 10 people) is hypertension (high blood pressure). 
Pogost neželeni učinek (pojavi se pri manj kot 1 od 10 ljudi) je hipertenzija (visok krvni tlak).
Misuse of MIRCERA by healthy people may lead to an excessive increase in haemoglobin. 
Zloraba zdravila MIRCERA pri zdravih osebah lahko povzroči čezmerno povečanje koncentracij hemoglobina.
The safety and efficacy of MIRCERA therapy has not been established in patients with haemoglobinopathies, seizures, bleeding or a recent history of bleeding requiring transfusions or with platelet levels greater than 500 x 109/l. 
Varnosti in učinkovitosti zdravljenja z zdravilom MIRCERA niso raziskali pri bolnikih s hemoglobinopatijami, epileptičnimi napadi, krvavitvami ali nedavno krvavitvijo, ki je zahtevala transfuzijo, ter pri koncentracijah trombocitov, večjih od 500 x 109/l.
If you do not respond adequately to MIRCERA, your doctor will check your dose and will inform you if you need to change doses of MIRCERA. 
Če se ne boste ustrezno odzvali na zdravilo MIRCERA, bo zdravnik preveril vaš odmerek in vam povedal, če boste morali spremeniti odmerke zdravila MIRCERA.
· Do not remove the needle shield until you are ready to perform an injection. 
· Ne odstranite igelne zaščite, dokler niste pripravljeni za dajanje injekcije.
Adverse reactions in Table 2 are listed according to MedDRA system organ class and frequency category. 
Neželeni učinki v preglednici 2 so navedeni po organskih sistemih MedDRA in pogostnosti.
Treatment with MIRCERA is not recommended in children and adolescents, because it has not been studied in these patients. 
Zdravljenje z zdravilom MIRCERA ni priporočljivo za bolne otroke in mladostnike, saj pri njih ni bilo raziskano.
Erythropoietin is a growth factor that primarily stimulates red cell production. 
Eritropoetin je rastni dejavnik, ki primarno stimulira tvorbo rdečih krvnih celic.
Do not allow the medicine to freeze, and protect the medicine from light. 
Zdravilo ne sme zmrzniti in zaščititi ga morate pred svetlobo.
Disinfect your hands well with soap and warm water or hands sanitizer. 
Roke si skrbno umijte z milom in toplo vodo ali dezinficirajte z razkužilom za roke.
Overdose can result in manifestations of an exaggerated pharmacodynamic effect, e.g. excessive erythropoiesis. 
Preveliko odmerjanje se lahko izrazi s pretiranim farmakodinamičnim učinkom, na primer s čezmerno eritropoezo.
Physical, cognitive, or sexual developments in the offspring of mothers receiving methoxy polyethylene glycol-epoetin beta during gestation and lactation were not affected. 
Telesni, kognitivni ali spolni razvoj potomcev samic, ki so prejemale metoksipolietilenglikol epoetin beta med gestacijo in laktacijo, ni bil prizadet.
To be sure the needle can be inserted correctly under the skin, use your free hand to pinch a fold of loose skin at the clean injection site. 
Da boste sigurni, da lahko iglo pravilno vstavite pod kožo, s prosto roko naredite kožno gubo na očiščenem mestu injiciranja.
During this period when you have stored MIRCERA at a room temperature not above 30 °C you may not put MIRCERA back in the refrigerator before use. 
V tem času, ko ste zdravilo hranili pri sobni temperaturi do 30 °C, pred uporabo zdravila ne smete vrniti nazaj v hladilnik.
· You should use a different injection site each time you administer an injection, at least three centimeters from the area you used for the previous injection. 
· Vsakič, ko si dajate injekcijo, si izberite drugo mesto injiciranja, ki je oddaljeno vsaj tri centimetre od prejšnjega mesta injiciranja.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
Take the needle out of the skin WITHOUT releasing the plunger. 
Iglo odstranite iz kože, BREZ da bi sprostili bat.
A reticulocyte count should be considered as part of the evaluation. 
Kot del ocenjevanja pride v poštev določanje števila retikulocitov.
Your doctor will decide to treat you with MIRCERA administered as a single injection once a month. 
Odločil se bo, ali vas bo zdravil z zdravilom MIRCERA v eni injekciji enkrat na mesec.